Scancell Holdings PLC (AIM:SCLP, FRA:SCP) (AIM:SCLP) said it will use PharmaJet’s needle-free technology to administer Covid vaccine candidates SCOV1 and SCOV2 in its COVIDITY phase I clinical trial.
Researchers will use either the Tropis system for intradermal delivery or the Stratis product for intramuscular use.
“Our preclinical studies have shown that delivery of SCOV1 and SCOV2 with the PharmaJet needle-free systems generate excellent T-cell and antibody responses,” said Scancell’s chief executive, Professor Lindy Durrant.